International Stem Cell Corporation (OTCBB:ISCO) today announced two new
international marketing initiatives. The first is the successful
conclusion of an agreement in principle to distribute its Lifeline Skin
Care product line in the United Arab Emirates via a strategic
relationship with noted facial plastic surgeon, Dr. Gregory S. Keller MD
of Los Angeles and Santa Barbara, CA. The second is the engagement of
Dr. K. McIsaac who will distribute Lifeline's products in Australia and
New Zealand under Lifeline's own brand name. These agreements mark the
first time that Lifeline Skin Care has distributed its products
overseas. Currently, Lifeline Skin Care products are sold in the United
States through the Company's website www.lifelineskincare.com.
The UAE represents an attractive market of some 4.3 million people, of
which nearly 75% are expatriates. This cosmopolitan market is one of the
most urbanized nations in the world with about 88% of its population
living in cities. It has one of the highest per capita incomes in the
world and an annual GDP growth rate at 8.8%.
"I am excited to introduce Lifeline Skin Care products to the UAE, and I
am confident that our customers there will enjoy the same kind of
satisfaction with the products as many of my patients in the United
States report," said Dr. Keller. "Many of my American patients have been
using these products since they were introduced on the market earlier
this year, and the results they've seen are amazing."
Dr. Ruslan Semechkin, CEO of Lifeline Skin Care commented: "Dr. Keller
has been a faithful supporter of our developmental and commercial
efforts in the United States, and he has witnessed the dramatic benefits
enjoyed by our customers. We are pleased that he has offered to bring
the benefits of Lifeline to the people of UAE.
"In choosing Dr. McIsaac and his marketing team, we believe we will be
able to rapidly grow sales and better serve the Australia and New
Zealand markets. Dr. McIsaac brings a wealth of experience in direct to
consumer sales and marketing. Together these agreements are a key part
of our strategy to internationalize our brand."
Lifeline® Skin Care is the only skin care line that is based on human
parthenogenetic stem cells that stimulate your skin's own abilities to
repair itself. Lifeline products are sold in pairs, including a day
cream and a night cream. A complete set is sufficient for one month of
regular use.
About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic
applications of human parthenogenetic stem cells (hpSCs) and the
development and commercialization of cell-based research and cosmetic
products. ISCO's core technology, parthenogenesis, results in the
creation of pluripotent human stem cells from unfertilized oocytes
(eggs). hpSCs avoid ethical issues associated with the use or
destruction of viable human embryos. ISCO scientists have created the
first parthenogenic, homozygous stem cell line that can be a source of
therapeutic cells for hundreds of millions of individuals of differing
genders, ages and racial background with minimal immune rejection after
transplantation. hpSCs offer the potential to create the first true stem
cell bank, UniStemCell™. ISCO also produces and markets specialized
cells and growth media for therapeutic research worldwide through its
subsidiary Lifeline Cell Technology, and cell-based skin care products
through its subsidiary Lifeline Skin Care. More information is available
at www.internationalstemcell.com.
To subscribe to receive ongoing corporate communications, please click
on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.
Forward-looking Statements
Statements pertaining to anticipated developments, potential sales
growth and other opportunities for the company and its subsidiaries,
along with other statements about the future expectations, beliefs,
goals, plans, or prospects expressed by management constitute
forward-looking statements. Any statements that are not historical fact
(including, but not limited to statements that contain words such as
"will," "believes," "plans," "anticipates," "expects," "estimates,")
should also be considered to be forward-looking statements.
Forward-looking statements involve risks and uncertainties, including,
without limitation, risks inherent in the development and/or
commercialization of potential products and the management of
collaborations, regulatory approvals, need and ability to obtain future
capital, application of capital resources among competing uses, and
maintenance of intellectual property rights. Actual results may differ
materially from the results anticipated in these forward-looking
statements and as such should be evaluated together with the many
uncertainties that affect the company's business, particularly those
mentioned in the cautionary statements found in the company's Securities
and Exchange Commission filings. The company disclaims any intent or
obligation to update forward-looking statements.
International Stem Cell Corporation
Kenneth
C. Aldrich, Co-Chairman
760-940-6383
kaldrich@intlstemcell.com
or
International
Stem Cell Corporation
Donna Queen, Vice President of
Marketing and Business Development
760-710-3295
dqueen@lifelineskincare.com
or
Lippert/Heilshorn
& Associates
Don Markley, 310-691-7100
dmarkley@lhai.com